OS Therapies (NYSE American: OSTX) has appointed Robert S. Langer, PhD, and co-founder of Moderna, to its strategic advisory board.
According to OS, Dr. Langer will assist management with prioritizing the listeria oncology pipeline, evaluating combinations of listeria product candidates with other oncology-focused biotechnologies, and selecting tunable Antibody Drug Conjugate (tADC) candidates for further development.
Dr. Langer, one of nine institute professors at the Massachusetts Institute of Technology, is internationally renowned in the field of biotechnology and has developed core technologies used for drug discovery and development to improve the health of millions worldwide.
In a statement, Dr. Langer commented, “The use of listeria monocytogenes as a vehicle to activate the immune system to kill cancer has been studied for decades but may soon become a medical reality thanks to OS Therapies. Listeria’s unique properties as an intracellular bacterium create major opportunities both to treat cancers which have not responded to existing immunotherapies and to enhance outcomes for patients already receiving other anti-cancer agents, given the strong safety profile exhibited in the Phase 2b study of OST-HER2 and the more than one thousand patients treated with the platform. I will be working with the OS Therapies team to implement a robust pipeline development strategy for both standalone and combination product development.”
He added, “Moreover, the unique properties of silicone dioxide that underlie the tADC linker/cap technology present tremendous opportunities to design more comprehensive and efficacious candidates which can deliver combinations of cytotoxic and immune stimulatory compounds in a targeted way: this means we can more effectively treat solid tumors and ultimately aim to improve patient outcomes.”
